Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth.
ADM shares down as CFO Vikram Luthar resigns effective Sept. 30, 2024. Luthar to receive $743K incentive for 2023 and remain as non-executive until then.